Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?

Detalhes bibliográficos
Autor(a) principal: Reis, Paulo Eduardo Ocke
Data de Publicação: 2020
Outros Autores: Lima, Marcos Cesar Braga
Tipo de documento: preprint
Idioma: eng
Título da fonte: SciELO Preprints
Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/518
Resumo: Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.
id SCI-1_d836b0cd76dd67f9809b62b2ab09af78
oai_identifier_str oai:ops.preprints.scielo.org:preprint/518
network_acronym_str SCI-1
network_name_str SciELO Preprints
repository_id_str
spelling Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?COVID-19coronavirusanticoagulantsthrombosispreventionhospital mortalityCOVID-19coronavirusanticoagulantsthrombosispreventionhospital mortalityMany patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-18info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/518enghttps://preprints.scielo.org/index.php/scielo/article/view/518/654Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessReis, Paulo Eduardo OckeLima, Marcos Cesar Bragareponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-18T19:21:23Zoai:ops.preprints.scielo.org:preprint/518Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-18T19:21:23SciELO Preprints - SciELOfalse
dc.title.none.fl_str_mv Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
title Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
spellingShingle Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
Reis, Paulo Eduardo Ocke
COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
title_short Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
title_full Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
title_fullStr Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
title_full_unstemmed Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
title_sort Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
author Reis, Paulo Eduardo Ocke
author_facet Reis, Paulo Eduardo Ocke
Lima, Marcos Cesar Braga
author_role author
author2 Lima, Marcos Cesar Braga
author2_role author
dc.contributor.author.fl_str_mv Reis, Paulo Eduardo Ocke
Lima, Marcos Cesar Braga
dc.subject.por.fl_str_mv COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
topic COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
COVID-19
coronavirus
anticoagulants
thrombosis
prevention
hospital mortality
description Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.
publishDate 2020
dc.date.none.fl_str_mv 2020-05-18
dc.type.driver.fl_str_mv info:eu-repo/semantics/preprint
info:eu-repo/semantics/publishedVersion
format preprint
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://preprints.scielo.org/index.php/scielo/preprint/view/518
url https://preprints.scielo.org/index.php/scielo/preprint/view/518
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://preprints.scielo.org/index.php/scielo/article/view/518/654
dc.rights.driver.fl_str_mv Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Lima
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Lima
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
dc.source.none.fl_str_mv reponame:SciELO Preprints
instname:SciELO
instacron:SCI
instname_str SciELO
instacron_str SCI
institution SCI
reponame_str SciELO Preprints
collection SciELO Preprints
repository.name.fl_str_mv SciELO Preprints - SciELO
repository.mail.fl_str_mv scielo.submission@scielo.org
_version_ 1797047817875750912

Registros relacionados